CMG Pharmaceutical Co. Ltd (058820) — Capital Reinvestment Ratio

Latest as of December 2024: 109.44x

CMG Pharmaceutical Co. Ltd (058820) has a Capital Reinvestment Ratio of 109.44x as of December 2024, meaning it reinvests 109% of its operating cash flow (₩290.09 Million) in capital expenditures (₩31.75 Billion). See CMG Pharmaceutical Co. Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

109.44x
Capex / Operating Cash Flow

Operating Cash Flow

₩290.09 Million
KRW

Capital Expenditures

₩31.75 Billion
KRW

Data as of

Dec 2024
Most recent filing

CMG Pharmaceutical Co. Ltd Capital Reinvestment Ratio (2014–2024)

This chart tracks CMG Pharmaceutical Co. Ltd's Capital Reinvestment Ratio across 11 annual periods.

Annual Capital Reinvestment Ratio for CMG Pharmaceutical Co. Ltd (2014–2024)

Year-by-year Capital Reinvestment Ratio for CMG Pharmaceutical Co. Ltd from 2014 to 2024. For live market cap and broader valuation context, see 058820 market cap.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2024 109.44x ₩290.09 Million ₩31.75 Billion ▲ +2706.1%
2023 3.90x ₩3.91 Billion ₩15.25 Billion ▲ +86.8%
2022 2.09x ₩4.94 Billion ₩10.31 Billion ▲ +197.4%
2021 0.70x ₩5.63 Billion ₩3.95 Billion ▼ -78.6%
2020 3.28x ₩2.94 Billion ₩9.65 Billion ▲ +13.2%
2019 2.90x ₩2.82 Billion ₩8.18 Billion ▲ +0.9%
2018 2.87x ₩886.78 Million ₩2.55 Billion ▲ +635.3%
2017 0.39x ₩1.95 Billion ₩760.59 Million ▲ +12.8%
2016 0.35x ₩2.31 Billion ₩799.00 Million ▼ -77.0%
2015 1.51x ₩2.41 Billion ₩3.64 Billion ▼ -88.4%
2014 13.00x ₩724.89 Million ₩9.42 Billion
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow